529 related articles for article (PubMed ID: 32005202)
41. Perspectives from health-care providers and women about completing human papillomavirus (HPV) self-testing at home.
Katz ML; Zimmermann BJ; Moore D; Paskett ED; Reiter PL
Women Health; 2017; 57(10):1161-1177. PubMed ID: 27700693
[TBL] [Abstract][Full Text] [Related]
42. Effect of HPV self-collection kits on cervical cancer screening uptake among under-screened women from low-income US backgrounds (MBMT-3): a phase 3, open-label, randomised controlled trial.
Pretsch PK; Spees LP; Brewer NT; Hudgens MG; Sanusi B; Rohner E; Miller E; Jackson SL; Barclay L; Carter A; Wheeler SB; Smith JS
Lancet Public Health; 2023 Jun; 8(6):e411-e421. PubMed ID: 37182529
[TBL] [Abstract][Full Text] [Related]
43. Prevention of cervical cancer in HIV-seropositive women from developing countries through cervical cancer screening: a systematic review.
Mapanga W; Girdler-Brown B; Feresu SA; Chipato T; Singh E
Syst Rev; 2018 Nov; 7(1):198. PubMed ID: 30447695
[TBL] [Abstract][Full Text] [Related]
44. A Qualitative Study of Parental Knowledge and Perceptions of Human Papillomavirus and Cervical Cancer Prevention in Rural Central Java, Indonesia: Understanding Community Readiness for Prevention Interventions.
Spagnoletti BRM; Bennett LR; Wahdi AE; Wilopo SA; Keenan CA
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2429-2434. PubMed ID: 31450917
[TBL] [Abstract][Full Text] [Related]
45. Study protocol of the ACCESS trial: a randomised trial to evaluate the effectiveness of human papillomavirus testing by self-sampling in cervical cancer screening uptake and precancer detection.
Fujita M; Shimazu M; Nagashima K; Suzuki M; Tauchi I; Sakuma M; Yamamoto S; Shozu M; Hanaoka H; Tsuruoka N; Kasai T; Hata A
BMJ Open; 2022 Feb; 12(2):e049803. PubMed ID: 35115348
[TBL] [Abstract][Full Text] [Related]
46. Comparing self- and provider-collected swabbing for HPV DNA testing in female-to-male transgender adult patients: a mixed-methods biobehavioral study protocol.
Reisner SL; Deutsch MB; Peitzmeier SM; White Hughto JM; Cavanaugh T; Pardee DJ; McLean S; Marrow EJ; Mimiaga MJ; Panther L; Gelman M; Green J; Potter J
BMC Infect Dis; 2017 Jun; 17(1):444. PubMed ID: 28645254
[TBL] [Abstract][Full Text] [Related]
47. Opportunities and challenges for introducing HPV testing for cervical cancer screening in sub-Saharan Africa.
Tsu VD; Njama-Meya D; Lim J; Murray M; de Sanjose S
Prev Med; 2018 Sep; 114():205-208. PubMed ID: 30031013
[TBL] [Abstract][Full Text] [Related]
48. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
[TBL] [Abstract][Full Text] [Related]
49. A Qualitative Exploration of Women's Experiences with a Community Health Volunteer-Led Cervical Cancer Educational Module in Migori County, Kenya.
Choi Y; Oketch SY; Adewumi K; Bukusi E; Huchko MJ
J Cancer Educ; 2020 Feb; 35(1):36-43. PubMed ID: 30368651
[TBL] [Abstract][Full Text] [Related]
50. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
51. Can Human Papillomavirus DNA Self-sampling be an Acceptable and Reliable Option for Cervical Cancer Screening in Female Sex Workers?
Wong ELY; Cheung AWL; Huang F; Chor JSY
Cancer Nurs; 2018; 41(1):45-52. PubMed ID: 28114260
[TBL] [Abstract][Full Text] [Related]
52. Field Evaluation of Xpert HPV Point-of-Care Test for Detection of Human Papillomavirus Infection by Use of Self-Collected Vaginal and Clinician-Collected Cervical Specimens.
Toliman P; Badman SG; Gabuzzi J; Silim S; Forereme L; Kumbia A; Kombuk B; Kombati Z; Allan J; Munnull G; Ryan C; Vallely LM; Kelly-Hanku A; Wand H; Mola GDL; Guy R; Siba P; Kaldor JM; Tabrizi SN; Vallely AJ
J Clin Microbiol; 2016 Jul; 54(7):1734-1737. PubMed ID: 27076663
[TBL] [Abstract][Full Text] [Related]
53. To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings.
Campos NG; Tsu V; Jeronimo J; Mvundura M; Lee K; Kim JJ
Int J Cancer; 2017 Mar; 140(6):1293-1305. PubMed ID: 27925175
[TBL] [Abstract][Full Text] [Related]
54. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
Hall MT; Smith MA; Lew JB; O'Hallahan J; Fentiman G; Neal H; Sage M; Canfell K
Gynecol Oncol; 2019 Mar; 152(3):472-479. PubMed ID: 30876491
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of the Impact of Human Papillomavirus DNA Self-sampling on the Uptake of Cervical Cancer Screening.
Wong EL; Chan PK; Chor JS; Cheung AW; Huang F; Wong SY
Cancer Nurs; 2016; 39(1):E1-E11. PubMed ID: 25730587
[TBL] [Abstract][Full Text] [Related]
56. The cost-effectiveness of human papillomavirus self-collection among cervical cancer screening non-attenders in El Salvador.
Campos NG; Alfaro K; Maza M; Sy S; Melendez M; Masch R; Soler M; Conzuelo-Rodriguez G; Gage JC; Alonzo TA; Castle PE; Felix JC; Cremer M; Kim JJ
Prev Med; 2020 Feb; 131():105931. PubMed ID: 31765712
[TBL] [Abstract][Full Text] [Related]
57. The Mulher Study: cervical cancer screening with primary HPV testing in Mozambique.
Salcedo MP; Lathrop E; Osman N; Neves A; Rangeiro R; Mariano AAN; Nkundabatware JC; Tivir G; Carrilho C; Monteiro ECS; Burny R; Thomas JP; Carns J; Andrade V; Mavume C; Paulo Mugolo R; Atif H; Hoover H; Chivambo E; Chissano M; Oliveira C; Milan J; Varon ML; Fellman BM; Baker E; Jeronimo J; Castle PE; Richards-Kortum R; Schmeler KM; Lorenzoni C
Int J Gynecol Cancer; 2023 Dec; 33(12):1869-1874. PubMed ID: 37907263
[TBL] [Abstract][Full Text] [Related]
58. The Vaccine and Cervical Cancer Screen project 2 (VACCS 2): Linking cervical cancer screening to a two-dose HPV vaccination schedule in the South-West District of Tshwane, Gauteng, South Africa.
Snyman LC; Dreyer G; Visser C; Botha MH; van der Merwe FH
S Afr Med J; 2015 Mar; 105(3):191-4. PubMed ID: 26294825
[TBL] [Abstract][Full Text] [Related]
59. Health impact of delayed implementation of cervical cancer screening programs in India: A modeling analysis.
Campos NG; Tsu V; Jeronimo J; Regan C; Resch S; Clark A; Sy S; Kim JJ
Int J Cancer; 2019 Feb; 144(4):687-696. PubMed ID: 30132850
[TBL] [Abstract][Full Text] [Related]
60. Facilitators and Barriers to HPV Self-Sampling as a Cervical Cancer Screening Option among Women Living with HIV in Rural Uganda.
Nyabigambo A; Mayega RW; Hlongwana K; Ginindza TG
Int J Environ Res Public Health; 2023 May; 20(11):. PubMed ID: 37297609
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
